Abstract | BACKGROUND: METHODS: Muscle bundles of 24 MH-susceptible patients with or without an RyR1 mutation, 35 MH-nonsusceptible and 10 MH-equivocal patients were exposed either to sevoflurane 8 vol% bolus or increasing doses of 2, 4, 6, and 8 vol%. In MH-positive patients, a screening for mutations in the RyR1 gene was performed. RESULTS: The in vitro parameters initial length, weight, predrug resting tension, and predrug twitch height did not differ between the groups. Sevoflurane caused significant contractures in MH-susceptible but not in MH-nonsusceptible muscle after increasing doses [1.4 (0.3-6.0) vs. 0 (0-0) mN] and after bolus application [6.9 (2.4-21.4) vs. 0 (0-0) mN]. However, only 50% of the susceptible patients developed contractures ≥ 2 mN after increasing concentrations while 83% did so after rapid bolus administration. Presence of an RyR1 mutation was detected in 36% of the examined MH-positive patients but had no influence on developing contractures. CONCLUSION:
|
Authors | S Johannsen, W Klingler, D Schneiderbanger, S Heiderich, N Roewer, F Schuster |
Journal | Acta anaesthesiologica Scandinavica
(Acta Anaesthesiol Scand)
Vol. 57
Issue 9
Pg. 1161-6
(Oct 2013)
ISSN: 1399-6576 [Electronic] England |
PMID | 23957432
(Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | © 2013 The Acta Anaesthesiologica Scandinavica Foundation. Published by John Wiley & Sons Ltd. |
Chemical References |
- Anesthetics, Inhalation
- Methyl Ethers
- Ryanodine Receptor Calcium Release Channel
- Sevoflurane
- Halothane
|
Topics |
- Anesthetics, Inhalation
- Biopsy
- Disease Susceptibility
(diagnosis)
- Dose-Response Relationship, Drug
- Genetic Predisposition to Disease
(genetics)
- Halothane
- Humans
- In Vitro Techniques
- Malignant Hyperthermia
(diagnosis, genetics)
- Methyl Ethers
- Muscle Contraction
(drug effects)
- Muscle, Skeletal
(drug effects)
- Predictive Value of Tests
- Ryanodine Receptor Calcium Release Channel
(genetics)
- Sevoflurane
|